Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zodasiran in Homozygous Familial Hypercholesterolemia (YOSEMITE)
NCT07037771Phase 3Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing zodasiran with Placebo (2 arms). Primary endpoint: Percent Change from Baseline in Fasting Low Density Lipoprotein Cholesterol at Month 12. Started Jun 2025; status: active, not recruiting.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT07037771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037771.